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Introduction
The increasing volume of  information published in
biomedical literatures poses an enormous challenge
to evidence-based health care and scientific discoveries.
It is common for important issues in medical research
to be addressed in several studies. The idea of
summarizing a set of studies is not new in medical
literature; review articles have long had an important
role in helping practitioners keep up to date and make
sense of the many studies on any given topic. Meta
analysis goes a step further by using statistical
procedures to combine the results of  several studies.
Definition
Several definitions exist in the literature. However,
Glass who developed the technique defined it as the
statistical analysis of  a large collection of  analysis results for the
purpose of  integrating the findings 1. Another author defined
it as a statistical procedure that integrates the results of
several independent studies considered to be
“combinable.”2. According to Medical Subject
Headings (MESH), meta-analysis is a quantitative
method of combining the results of independent
studies (usually drawn from published literature) and
synthesizing summaries and conclusions which may
be used to evaluate therapeutic effectiveness, plan new
studies, etc., with application chiefly in the areas of
research and medicine 3. Well conducted meta-analyses
allow a more objective appraisal of the evidence than
traditional narrative reviews, provide a more precise
estimate of a treatment effect, and may explain
heterogeneitybetween the results of  individual studies.
Ill conducted meta-analyses, on the other hand, may
be biased owing to exclusion of relevant studies or
inclusion of inadequate studies4. Misleading analyses
can generally be avoided if a few basic principles are
observed.This review article discusses these principles,
along with the steps in performing meta-analysis. It
concludes by highlighting the future and role of meta-
analysis in medical discoveries.
Evolution in Medicine
The first meta-analysis was a combination of studies
(with small sample sizes) of typhoid vaccine
effectiveness performed by Karl Pearson in 19045 in
an attempt to overcome the problem of reduced
statistical power. Although meta-analysis is widely used
in epidemiology and evidence-based medicine today,
a meta-analysis of a medical treatment was not
published until 1955. The term was coined by Glass1
in 1976, even though some meta-analytic methods have
been in use for almost fifteen years in Education and
Psychology. The concept made its way into medicine
as researchers began to incorporate the idea. At the
onset, the concept was not popular among medical
scientists until mid 1980s when a group of clinicians
and statisticians at Oxford University initiated the
process of giving it scientific prominence. The Oxford
group took the approach of gathering all studies,
published and unpublished, and excluding those that
used different endpoints. They focused on studies of
therapeutic issues6. Their conclusions were applied by
others to clinical practice, to further ascertain validity.
By 1985, there was a book on statistical methods for
meta-analysis 7. In addition, there was a 1985
publication, “Findings for Public Health from Meta-
analysis” which clarifies the difference between meta-
analysis and traditional literature review. Since then, the
technique has grown in leaps and bounds with
application in different areas of medicine and other
specialties. Its statistical methodology is always reviewed
and constantly improved to accommodate new realities.
For the results of  a meta-analysis to be meaningful, a
great deal of thought and planning are needed.
Protocols for the reporting of meta-analysis results
were developed for Randomized Clinical Trials (RCTs)
(Quality of Reports of Meta-analysis [QUOROM])8
and observational studies (Meta-analysis of
Observational Studies in Epidemiology [MOOSE])9.
These guidelines were developed to provide proper
procedures for conducting a meta-analysis and to
standardize the methods of reporting it. Using these 2
protocols as a guide, the steps necessary to perform a
meta-analysis include the following: (1) define the
research question, (2) perform the literature search, (3)
select the studies, (4) extract the data, (5) analyze the
data, and (6) report the results.
Define the Research Question
A meta-analysis begins with a question. Common
questions addressed in meta-analyses are whether one
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treatment is more effective than another or if exposure
to a certain agent will result in disease. Before beginning
an analysis, the investigators need to define the problem
or question of interest. The investigators should also
have a good understanding of the problem and the
subject matter10. The study population baseline data
(e.g., age, race, gender, diagnosis, length of  illness), the
study outcomes, treatment or intervention, and type
of  study designs to be used (e.g., restricted to RCTs
or include observational studies such as prospective
or retrospective studies) also should be defined11.
Perform the Literature Search
Once the research question has been defined, a
systematic search of the literature can begin. This is a
critical step in the meta-analysis and often the most
difficult part. The initial search of the literature should
be broad so that as many studies as possible are
gathered. During the selection phase, some of the initial
studies will be weeded out using the inclusion criteria.
The literature search begins with searching electronic
databases of published studies such as MEDLINE,
EMBASE, CINAHL, etc. MEDLINE is maintained
by the National Library of Medicine and contains more
than 13 million citations dating back to 196612.
EMBASE is a database produced by the publisher
Elsevier BV and contains data from 1974 to the
present13. Although EMBASE and MEDLINE
overlap in their coverage of the literature, EMBASE
has better coverage of European journals14. CINAHL
covers literature related to nursing and allied health
from 1982 to the present15. The researchers should
search more than just MEDLINE to ensure a
comprehensive search. For example, a report found
that approximately only half  of  all RCTs presented as
abstracts are subsequently published on MEDLINE16.
It is necessary to use other sources to access many of
these unpublished studies. A good source for
unpublished clinical trials is the Cochrane Central
Register of  Controlled Trials, which is a database of
controlled trials. The database was set up to provide a
source of data for systematic reviews and contains
more than 300,000 references to RCTs17. Other
suggestions for locating studies include searching
reference lists from the gathered reports, manually
searching journals with lists of abstracts presented at
meetings, or searching on the Internet. Contacting
experts in the field or networking with colleagues also
could be a source of studies, although this mode of
data gathering is seldom used.
Select the Studies
Once the literature search is complete, it is time to
select which studies to include in the meta-analysis. The
inclusion and exclusion criteria for studies need to be
defined at the beginning, during the design stage of
the meta-analysis. Factors determining inclusion in the
analysis are study design, population characteristics, type
of treatment or exposure, and outcome measures 18.
The inclusion and exclusion criteria should be part of
the meta-analysis protocol. One should keep track of
the studies included and excluded at each step of the
selection to document the process. The QUOROM
guidelines for reporting a meta-analysis request that
investigators provide a flow diagram of the selection
process8. The flow diagram lists the number of studies
excluded and included at each stage of the selection
process and the reasons for exclusion. The selection
process involves reviewing the titles and abstracts of
all articles identified through the literature search.
Many of the studies will be excluded at this stage based
on the exclusion criteria. The remaining studies will be
read to determine their suitability for inclusion. The
validity of a meta-analysis depends on the quality of
the studies included, and an assessment of quality is a
necessary part of  the process. The researcher wants to
include as many studies as possible, but reduce the
number of studies with low quality data; however,
restricting the meta-analysis to only perfect studies may
leave the researcher with little data19. A variety of
checklists and scales have been developed to assess
quality in RCTs20. Checklists provide guidelines as to
what should be reported in an RCT, whereas scales
are a way of  quantifying the level of  bias in an RCT.
For example, a scale will assign a score based on a
specific characteristic of  an RCT (e.g., presence of
adequate concealment of patient assignment to
treatment groups), but a checklist does not assign scores.
Although quality needs to be assessed in some way,
caution should be used when using these scales or
checklists20, 21. The reasons for the inclusion of items in
a scale or checklist often are not given and the score
assigned to scales can be arbitrary20. The relatively
imprecise scoring scheme in some of the scales may
change the results of a meta-analysis21.
There are several options available to deal with study
quality once it has been ascertained. A cut-off value
for the quality score can be used to exclude or include
studies19, 22. Another choice is to use the quality scores
to weight study results in the analysis. MOOSE
reporting guidelines, however, recommend using a
sensitivity analysis rather than weighting for quality
scores9. Sensitivity or subgroup analysis allows
comparisons between studies of  different quality22. For
example, studies can be separated into high versus low
quality and then the meta-analysis can be repeated for
each group. Results then can be compared between
the 2 groups. A method that is being used increasingly
is meta-regression. Quality scores or some measure
of  study quality (e.g., assignment to a treatment group)
are entered into a regression model as an explanatory
variable19. This method allows the researchers to
estimate the effect of quality on the results of the meta-
analysis.
Extract the Data
The type of data to be extracted from each study
should be determined in the design phase and a
standardized form is constructed to record the data.
Examples of data commonly extracted include study
design, descriptions of  study groups (e.g., number in
each group, age, gender), diagnostic information,
treatments, length of follow-up evaluation, and
                                                   Annals of Ibadan Postgraduate  Medicine. Vol.6 No.1 June, 2008    28
outcome measures. Two independent reviewers will
be instructed on the appropriate data to collect. For
example, how will age be recorded on the abstract
form? Will the standard deviation or standard error
be used in the analysis? If data are missing, they should
be recorded on the form. If  too much data are
missing, the study may need to be excluded. It is
recommended that the reviewers be blinded to the
investigators’ names but it is not essential7, 23. Data to
be extracted are identified before beginning the meta-
analysis to avoid data dredging or a fishing expedition.
The difficulty with data extraction is that studies often
use different outcome metrics, which make combining
the data awkward. The data should be converted to a
uniform metric for pooling. For example, data
reported may be continuous (e.g., blood pressure) or
binary (e.g., high blood pressure vs low blood pressure).
A meta-analysis estimating the effect of a medication
on blood pressure may find some studies reporting
blood pressure as a continuous outcome whereas in
other studies the outcome is reported only as high or
low blood pressure. In this case it would be necessary
to convert continuous blood pressure measurements
into categories of high or low blood pressure to
standardize the data into one format. Similarly, some
studies report the standard deviation and others report
standard error. Again, it is necessary to convert one
into the other to make the data uniform. Although it
is difficult to resist combining the data, if combining
data is not possible because different metrics are used
then it is best to leave the analysis as a systematic review.
Analyze the Data
A statistician who is familiar with meta-analysis should
be consulted to help plan this type of project and to
participate in analyzing the data. Detailed instructions
for data analysis exist 19, 24 – 26. A meta-analysis calculates
a weighted average of the study effect that is pooled
from the selected studies. The weight is directly
proportional to the precision of the effect estimate
and usually the inverse of the variance (square of the
standard error) of the effect estimate19. Therefore,
larger studies will have more influence over the
summary estimate than smaller studies23. A summary
estimate is calculated by multiplying each study’s weight
by its effect estimate and adding these values together.
This sum then is divided by the sum of the study
weights. There are 2 statistical models used in a meta-
analysis: fixed effects and random effects. The fixed-
effects model assumes that the true effect of treatment
is the same for every study. Because there is no
heterogeneity between study results, only within-study
variability is taken into account. Given the degree of
variation or heterogeneity among studies, this
assumption may be unreasonable. The random-effects
model is often more realistic because it assumes that
the true effect estimate for each study does vary. Sources
of variation may include differences in patient
population or treatment methods. The random-effects
model will produce an estimate with wider confidence
intervals, but the summary estimates for both models
will be similar if there is not a great deal of
heterogeneity among studies. A statistical test for
heterogeneity can be used, but this test has low statistical
power in most cases19. Power refers to the ability of  a
statistical test to reject the hypothesis being tested (null
hypothesis) when it is false. The null hypothesis states
that there is no heterogeneity or variation among the
studies. Low power for the heterogeneity test means
that we are unable to reject the null hypothesis of no
heterogeneity even when important heterogeneity exists.
For example, the studies used in the meta-analysis may
in reality vary considerably, but the low power makes
the heterogeneity test non-significant. This would lead
the researcher to the incorrect conclusion that the
amount of  variation among the studies is low. The
best choice may be to always use the random-effects
model or to use both models and compare the results.
Statistical packages are available to calculate summary
estimates using either model. If heterogeneity can be
explained, then it should be included in the model.
For instance, we may observe that some of  the variation
in studies can be explained by gender. In that case,
separate summary estimates can be calculated for males
and for females. Or, meta-regression models can be
used to explain heterogeneity, but a large number of
studies are needed when investigating multiple effects.
Report the Results
Detailed guidelines for the reporting of meta-analyses
for RCTs were described in the QUOROM statement8.
Similar guidelines were developed for observational
studies by the MOOSE group9. These articles should
be consulted during the design phase to ensure that
these reporting procedures are used and that proper
data are collected and presented in the report. Similar
to a research report, a meta-analysis report should
include a title, abstract, and introduction, and methods,
results, and discussion sections. The title should identify
the report as a meta-analysis. The introduction should
indicate the clinical question of interest, the hypothesis
being tested, the types of treatment or exposure being
studied, the study designs to be included, and a
description of the study population. The methods
section should describe the literature search, specifically
the databases used, and if the search was restricted in
any way (e.g., English language only). The selection
process for articles, quality assessment, methods of
data abstraction, and synthesis also should be described
in this section. The results section should include a flow
chart of studies included in each step of the selection
process, a figure displaying the results from each
individual study such as a forest plot, results of
heterogeneity testing, overall summary statistic and its
95% confidence interval, and results of  a sensitivity
analysis and meta-regression, if  performed. For
sensitivity analysis, several features of a meta-analysis
can be altered to assess the robustness of the results,
such as excluding questionable or unpublished studies.
The sensitivity analysis may include an analysis weighted
by a quality score for each study. The discussion section
should summarize the key findings and identify possible
sources of  bias and heterogeneity. A forest plot, the
figure with the effect estimate from each study and
their associated confidence intervals along with the
                                                   Annals of Ibadan Postgraduate  Medicine. Vol.6 No.1 June, 2008    29
summary estimate, is an important part of the report.
Studies can be grouped by size or by other study
characteristics such as year of publication. It allows
the reader to observe the heterogeneity of  the studies
included. If  the confidence intervals for effect
estimates are not overlapping, indicating a great deal
of study variation, a meta-analysis may not be
appropriate. In this case, it is necessary to explore the
reasons for the variation among the studies, which may
lead to the discovery of associations between the study
design or patient groups and the study outcome.
A funnel plot is used as a way to assess publication
bias in a meta-analysis. The funnel plot is a scatter plot
of  each study’s effect estimate (e.g., odds ratio or mean
difference) on the x-axis against a measure of  the study’s
precision on the y-axis 19, 27. The overall sample size
can be used on the y-axis but often an inverse of the
standard error is used28. If a publication bias is not
present, the plot will resemble an inverted funnel. Large
studies should have smaller variation and therefore a
more precise effect estimate, whereas small studies
should have larger variation and therefore a less-precise
estimate. One expects the effect estimates for small
studies will have wider scatter at the bottom of the
plot and larger studies will have less scatter at the top
of the plot. If small studies with negative or null results
tend not to be published, one would see asymmetry
in the funnel plot from the left bottom of the plot
containing few or no data points. On the other hand,
if fewer studies with non-statistically significant odds
ratios were included in the literature search, it would
result in an asymmetric funnel plot. Funnel plots can
be inspected visually but interpretation can differ from
person to person. Statistical tests such as the rank
correlation test developed by Begg and Mazumdar29
are available to assess the symmetry of the plot. The
correlation test, however, should be used with caution
in small meta-analyses because the power of the test
depends on the number of studies included29. In a
small meta-analysis (25 studies), the correlation test will
have low statistical power so a non-significant test will
not rule out bias in the literature search.
A meta-analysis is a statistical method of combining
results from multiple studies to determine the overall
impact of  a treatment or exposure. If  performed
properly, using the steps above, a meta-analysis can be
a powerful research tool. Although meta-analyses are
considered to have the highest level of evidence and
are cited more often than other study designs, there
are still lingering questions regarding its validity when
compared with well-conducted clinical trials 30, 31. The
results from a meta-analysis can be used to plan a large
RCT to test a treatment effect; however, a report
comparing the results from meta-analyses and
subsequent RCTs found only fair agreement32. The
distrust of meta-analyses and the lack of agreement
with RCTs do not imply that the meta-analysis should
be abandoned. It does, however, point out the
limitations and biases involved with the meta-analysis
and shows the need for conducting a thoughtful, well
planned meta-analysis with minimal bias. When
performed appropriately, however, a meta-analysis can
lend evidence to many of the difficult decisions clinicians
made in their daily practice.
Recent Development and Future of Meta-
analysis
In a review of recent developments in meta- analysis,
Stutton et al33 noted that there is considerable research
activity in the field of  meta-analysis. Meta-analysis
methodologies are being developed for concepts such
as prospective meta-analysis, meta-analysis of
individual patient data, etc. There are meta-analysis
techniques for complex evidence synthesis which
involve models that incorporate evidence on multiple
parameters and/or that specifically model data from
different study designs. There are developments in
meta-analyses of  studies on effects of  interventions,
aetiology, diagnosis and screening. A recent publication
of recommendations for reporting tumor marker
prognostic studies was reputed to be a good initiative
that will aid the meta- analysis of such studies in the
future34.
There are notable developments in software for meta-
analysis as well. However, due to the fact that meta-
analysis of summary data needs a unique set of analysis
tools, the large developers of general statistical software
have been reticent about providing the required
routines. Fortunately, users have developed collections
of  macros, e.g. for SAS35–37 and, most comprehensively,
for STATA38. Stand-alone packages have also been
developed, the most sophisticated of which is probably
the commercial Comprehensive Meta Analysis39. The
Cochrane Collaboration software, RevMan 40,
continues to be developed and a new freely
downloadable Excel add-in MIX41 offers excellent
functionality and educational content for those on a
tight budget. Sutton et al33 reported that they found
MetaDiSc42 very useful for carrying out the specialized
analyses required for diagnostic tests meta-analyses
There is little doubt that the development of meta-
analytic techniques will continue into the future. Multiple
treatment comparisons will receive greater attention
as it has potential to address the relative benefits of
competing treatments, and address questions such as
the probability that a particular treatment is superior
to all the alternatives.
CONCLUSION
The potential of meta-analysis for discovery was
demonstrated in the recent discovery of ten new genes
related to human growth which was published in the
latest issue of Nature Genetics43. There is no doubt
that meta-analyses have many positive attributes. Busy
physicians have difficulty keeping abreast of the huge
volume of medical literature, and some may not
possess the analytic skills to resolve the often non-
definitive or conflicting findings. Meta-analysis provides
an attractive solution to this problem. By examining
the totality of data available about an issue, meta-
analysis can identify inadequacies in existing data and
point to areas of needed research, reduce the potential
for erroneous findings occurring by chance, and more
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accurately define the benefit and possible adverse
effects of management strategies44. In fact, by
combining smaller datasets, meta-analysis may establish
unrecognized outcomes, may provide evidence of
statistical significance where it was previously absent,
or may eliminate any possible bias in individual studies.
Although, there are weaknesses such as publication
bias, citation bias, etc; in spite of these, meta-analysis
has a promising future for biomedical research and
development.
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